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Abstract
Background: Psychosocial symptoms often cluster together, are refractory to treat-
ment, and impair health- related quality of life (HR- QoL) in cancer patients. The 
contribution of circadian rhythm alterations to systemic symptoms has been over-
looked in cancer, despite a causal link shown under jet lag and shift work conditions. 
We investigated whether the circadian rest- activity rhythm provides a reliable and 
objective estimate of the most frequent patient- reported outcome measures (PROMs).
Methods: Two datasets were used, each involving concomitant 3- day time series of 
wrist actigraphy and HR- QoL questionnaires: EORTC QLQ- C30 was completed 
once by 237 patients with metastatic colorectal cancer; MD Anderson Symptom 
Inventory (MDASI) was completed daily by 31 patients with advanced cancer on 
continuous actigraphy monitoring, providing 1015 paired data points. Circadian 
function was assessed using the clinically validated dichotomy index I < O. 
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1 |  INTRODUCTION
Currently, one in eight adults carries wearable “well- being” 
activity monitors,1 with some 50 million such units been sold 
in the United States in 2016.2 This positive perception of e- 
Health devices in the general population represents an op-
portunity for implementing objective measures of physiology 
and behavior complementing the assessments of symptoms 
and health- related quality of life (HR- QoL), especially in 
cancer patients.3 Indeed, systemic psychosocial symptoms 
are usually subjectively rated using validated questionnaires 
evaluating patient- reported outcome measures (PROMs).4 
More specifically, fatigue, sleep disturbance, depression, and 
anorexia represent the most frequent psychosocial complaints 
of cancer patients.5 Extensive research has shown that can-
cer patients tend to display multiple systemic symptoms that 
often cluster together.6 Fatigue, anorexia, and affective disor-
ders can also arise as a consequence of anticancer treatment, 
suggesting shared physiopathological mechanisms.7 Such 
systemic ailments also reveal the disruption of those body 
clocks that time behavioral and cellular activities along the 
24- hour cycle, for example, as a consequence of jet lag or 
shift work.8-11 All living beings, from unicellular organisms 
to humans, are endowed with endogenous biological clocks 
that enable living organisms to anticipate cyclic environ-
mental changes and coordinate physiological events.12 The 
mammalian circadian timing system (CTS) is hierarchically 
organized and temporally controlled, and it coordinates sev-
eral physiological processes, at whole- body, cellular, down to 
molecular, levels.13,14 In particular, sleep- wake cycles, phys-
ical and mental performance, as well as appetite, are modu-
lated along the 24 hours by the CTS.15,16 As altered patterns 
have been described for several circadian rhythms in cancer 
patients,15,17,18 we hypothesized that systemic symptoms 
would be more severe in patients with circadian disruption. 
Two independent datasets were used to test this hypothesis. 
Based on the convenience of its noninvasive methodology 
and previous reports in smaller cohorts showing an associ-
ation with fatigue and sleep problems,19-25 we selected the 
circadian rest- activity rhythm as measured by wrist actigra-
phy.26,27 Wrist actigraphy has been validated as an objective 
biomarker of circadian function.28 Finally, objective actigra-
phy data were correlated with selected subjective PROMs, 
including systemic symptoms and HR- QoL domains.
2 |  PATIENTS AND METHODS
2.1 | Study populations
For this study, we used datasets from two patient cohorts, 
involving different PROMs tools and methodologies. The 
original data were available for both objectively assessed 
circadian rest- activity rhythm (wrist actigraphy)28 and sub-
jectively rated symptoms as well as HR- QoL (with validated 
questionnaires) from the same patients. For both patient co-
horts, approval had been obtained from the appropriate ethi-
cal review boards, and patients had provided signed informed 
consent.29-31
2.1.1 | Cohort #1
The first set was composed of patients with metastatic colo-
rectal cancer, who were not at time of monitoring having 
Nonparametric tests compared PROMs and I < O. Effect sizes were computed. 
Sensitivity subgroup and temporal dynamics analyses were also performed.
Results: I < O values were significantly lower with increasing symptom severity and 
worsening HR- QoL domains. Fatigue and anorexia were worse in patients with cir-
cadian disruption. The differences were both statistically and clinically significant 
(P < 0.001; d ≥ 0.33). Physical and social functioning, and global quality/enjoyment 
of life were significantly better in patients with robust circadian rhythm (P < 0.001; 
d ≥ 0.26). Sensitivity analyses validated these findings.
Conclusion: Objectively determined circadian disruption was consistently and ro-
bustly associated with clinically meaningfully severe fatigue, anorexia, and interfer-
ence with physical and social functioning. This supports an important role of the 
circadian system in the determination of cancer patients’ HR- QoL and symptoms that 
deserves therapeutic exploitation.
K E Y W O R D S
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anticancer treatment and had a WHO performance status 
of 0, 1, or 2. They had participated to either a monocentric 
study from May 1994 to January 1997 (Chronotherapy Unit, 
Department of Medical Oncology, Paul Brousse University 
Hospital, Villejuif, France)31 or to a companion study of an 
international randomized trial involving nine institutions in 
four countries, from August 1999 to February 2002.29
Patients in both studies underwent wrist actigraphy 
monitoring for 72 consecutive hours (Mini- motionlogger, 
Ambulatory Monitoring Inc., Ardsley, NY, USA) and com-
pleted the European Organization for Research and treatment 
of Cancer Quality of Life Core (EORTC QLQ- C30 v2.0) 
questionnaire.32 This internationally validated 30- item ques-
tionnaire incorporates eight symptoms, five functioning do-
mains and one global QoL scale. All scores were transformed 
to a 0- 100 scale, according to the recommended EORTC pro-
cedures. For the symptom scales, low scores corresponded to 
mild symptoms, whereas for the global QoL and its domains 
scales, low scores indicated poor functioning.32 In the anal-
ysis, we selected the systemic symptoms (fatigue, anorexia, 
sleep problems, pain), global QoL, and the functioning do-
mains (physical, role, and social), corresponding to the items 
in the M.D. Anderson Symptom Inventory (MDASI).33
2.1.2 | Cohort #2
The second set included patients with histologically proven 
advanced or metastatic cancer requiring medical treatment. 
The patients had participated to the pilot project on multi-
dimensional tele- monitoring from home performed at the 
Chronotherapy Unit, Department of Medical Oncology, Paul 
Brousse University Hospital, Villejuif, France, between April 
2012 and July 2013, within the framework of the inCASA 
European project (FP7).30 The patients were equipped with 
a home- based platform for multidimensional tele- monitoring 
over at least 30 consecutive days. This remote surveillance 
included continuous wrist actigraphy (Micro- motionlogger, 
Ambulatory Monitoring Inc., Ardsley, NY, USA) and once- 
daily completion of an electronic version of the MDASI 
questionnaire33 using an interactive screen. This 19- item 
validated questionnaire evaluates the severity (from 0 to 10) 
of 13 core symptoms and of their interference with six activi-
ties of daily living. Large scores for each item indicate severe 
symptoms.33 Patients were monitored while being treated 
with chemotherapy, as indicated according to their medical 
condition.30 Hence, this data- dense study provided dynamic 
patterns of circadian rest- activity rhythm and PROMs. As 
both circadian rest- activity rhythm and symptom severity on 
chemotherapy are not stationary and present temporary varia-
tions,34 we did not pool all data from a single patient over the 
monitoring span (exceeding 30 days). Instead, we analyzed 
actigraphy data over 72 consecutive hours, with 3- day slid-
ing windows and a 1- day shift, throughout the time series 
in each patient, and used individual daily data in MDASI 
items scores, as previously described.30 Hence, this dataset 
provided a larger amount of data than the actual number of 
patients. For the analysis, we selected the systemic symptoms 
(fatigue, anorexia, sleep disturbance, pain) and the interfer-
ence items (general activity, work, relations with others, 
and enjoyment of life), corresponding to the items from the 
EORTC questionnaire.
Among both cohorts, there were no uncontrolled meta-
bolic, endocrine, or autoimmune diseases and no symptom-
atic brain metastases (the details are provided in the original 
papers29-31).
Figure S1 displays the study flowchart.
2.2 | Wrist actigraphy
The wrist- worn accelerometers used in both cohorts were 
manufactured by the same company (Ambulatory Monitoring 
Inc., Ardsley, NY, USA), which provided also the dedicated 
analytical software (Action 4). In the second cohort study, 
the patients downloaded and tele- transmitted the rest- activity 
data collected over the past 24 hours using the home Internet 
platform.30 For both cohorts, the epoch length for data col-
lection was set at 1 minute, according to common practice.28 
The actigraph collects and stores the number of wrist ac-
celerations per minute, across the three axes, from the non-
dominant arm. The pattern of accelerations over time is then 
analyzed to compute pertinent parameters for assessing cir-
cadian rest- activity rhythm, over 72 consecutive hours, as 
recommended.28
2.3 | Statistical analyses
We selected the dichotomy index I < O as the most clinically 
relevant actigraphy parameter, based on prior studies from 
others and ourselves.29-31,35-38 I < O is the percentage of ac-
tivity counts per minute when the patient is in bed at night 
with values lower than the median activity count when the 
patient is out of bed during the day.39 Hence, it can range 
from 0% to 100%. In case of restful sleep at night and lively 
activity during the day, a robust and prominent circadian 
rhythm is present, and I < O will be close to 100%.39 To cat-
egorize patients with circadian disruption or not, we used the 
cut- off point for I < O of 97.5%, as previously identified and 
validated.36,37 Thus, when I < O was lower or equal to 97.5% 
we estimated that circadian rest- activity rhythm disruption 
was present, whereas this rhythm was deemed maintained 
when I < O was greater than 97.5%.
Summary statistics were computed to describe the distri-
bution of I < O values (median and interquartile range) and 
of PROMs (means, SD, and SEM). First, we categorized the 
PROMs items into terciles, and compared the distributions 
of I < O among the terciles with the Jonkheere- Terpstra 
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test. Secondly, we defined two categories of patients using 
the previously established cut- off point of 97.5% for I < O 
as a marker of circadian disruption. The distribution of 
the EORTC or the MDASI items were compared between 
the two groups, using an independent sample t test. We 
also evaluated the effect size of the difference in PROMs 
scores between the two groups by computing Cohen’s d, 
with a threshold for clinically meaningful difference set at 
d ≥ 0.25. Additionally, we assessed the clinical relevance 
of the absolute differences based on previously identified 
thresholds: 10 points for the EORTC questionnaire and one 
point for the MDASI scale, respectively.40,41 We used also 
the nonparametric Mann- Whitney U test to compare ques-
tionnaires items according to I < O category, as sensitivity 
analysis. For cohort #1, we performed subgroup analysis 
according to sex, PS, and age, using the same methodology. 
For cohort #2, we performed additional comparisons of the 
dynamic patterns of PROMs and I < O. Thus, we computed 
the differences in I < O between each day and the previous 
one, with a sliding window approach. The distribution of 
changes in selected PROMs was compared in each of the 
three subgroups defined by the terciles of the changes in 
I < O (improved, stable, worsened) with Wilcoxon signed- 
rank test.
Moreover, Spearman’s rank correlations between I < O 
and selected PROMs indices were computed for each cohort. 
Finally, we built a multivariate linear regression model with 
global quality of life (for cohort #1) or interference with en-
joyment of life (for cohort #2) as dependent variables, and all 
the other selected PROMs of each questionnaire and I < O 
as independent variables, to assess the objective, additional 
information about HR- QoL provided by I < O. Analyses 
were performed using PASW v24 (SPSS, IBM Inc., Chicago, 
IL, USA) and Stata v14 (StataCorp LLC, College Station, 
TX, USA) software packages. The threshold for statistical 
significance was set at P ≤ 0.005, correcting for multiple 
comparisons.
3 |  RESULTS
3.1 | Study populations
Study cohort #1 included 237 patients with metastatic colo-
rectal cancer, who completed the EORTC QLQ- C30 ques-
tionnaire and underwent 3- day wrist actigraphy recording 
(Table S1). Study cohort #2 included 31 patients, mostly suf-
fering from advanced or metastatic gastro- intestinal malig-
nancy and having 1015 valid dyads of 3- day wrist actigraphy 
recordings and daily completion of the MDASI question-
naire, at the intermediate day of the 3- day actigraphy sliding 
window (Table S1). Altogether, nearly 90% of the patients in 
either population had a performance status of 0 or 1, despite 
advanced disease (Table S1).29-31
3.2 | Descriptive statistics
Table S2 provides mean and SD values for EORTC symptom 
scales and quality of life domains (range, 0 to 100) in cohort 
#1, and for MDASI items (range, 0 to 10) in cohort #2 (Table 
S2).
The cut- off points for the terciles of PROMs are detailed 
in Table S3.
In both populations, the distribution of I < O values was 
skewed toward high values, as in previous reports38,42 (Figure 
S2). Median values, in both cases, were close to 97.5%, for-
merly reported as a clinically meaningful cut- off point36,37: 
96.9% [1st and 3rd quartiles: 93.6%- 99.1%] for cohort #1, 
and 98.0% [95.8- 99.0] for cohort #2 (Figure S1). Thus, the 
proportion of instances with circadian disruption (ie, with 
I < O ≤ 97.5%) was 54.9% in cohort #1 and 44.4% in cohort 
#2.
3.3 | Comparative analyses of wrist 
actigraphy monitoring and questionnaires
In cohort #1, I < O significantly decreased with increasing 
severity of fatigue (P < 0.0001), anorexia (P < 0.0001), pain 
(P < 0.0001), and sleep trouble (P = 0.003) (Figure 1A). In 
contrast, I < O significantly increased with greater values of 
global quality of life (P < 0.0001), physical (P < 0.0001), 
and social (P < 0.0001) functioning, but not role (P = 0.02) 
functioning (Figure 1B). In cohort #2, significantly lower 
I < O values were observed with gradually more severe fa-
tigue and anorexia, as well as interference with enjoyment of 
life, activity, relations with others, and work (all P < 0.0001), 
whereas differences were not significant for sleep disturbance 
(P = 0.56) and pain (P = 0.009; Figure 1C,D).
The comparison of PROMs as a function of circadian 
disruption (I < O ≤ 97.5%) or robustness (I < O > 97.5%) 
yielded similar results. Thus, in cohort #1, patients with 
circadian disruption complained of statistically more se-
vere fatigue (P < 0.0001), anorexia (P < 0.0001), and pain 
(P < 0.0001), yet only a nonsignificant trend (P > 0.005) 
was found for sleep trouble (P = 0.009). In cohort #2, fatigue 
(P < 0.0001) and anorexia (P < 0.0001) were also rated as 
significantly more severe when I < O ≤ 97.5%, whereas 
sleep disturbance (P = 0.61) and pain (P = 0.02) were not.
In cohort #1, global quality of life (P < 0.0001), phys-
ical functioning (P < 0.0001), and social functioning 
(P < 0.0001) were rated as significantly poorer by patients 
with I < O ≤ 97.5% as compared to those with higher 
I < O values, whereas role functioning (P = 0.04) was 
not. In cohort #2, instances with circadian disruption were 
significantly associated with greater interference with en-
joyment of life, activity, relations with others, and work 
(all P < 0.0001). The associated effect sizes were of inter-
mediate magnitude in both populations for the statistically 
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different items (Table 1). Figure 2 displays the mean 
(±SEM) values for both populations for selected corre-
sponding symptoms (panel A) or functioning/interference 
items (panel B).
Correlative analyses further confirmed a negative asso-
ciation between I < O and the severity of self- rated fatigue 
and anorexia, in both populations (Table 2). I < O was also 
found negatively correlated with pain and sleep trouble, and 
positively correlated with global quality of life, physical, so-
cial, and role functioning in cohort #1. In cohort #2, I < O 
was negatively correlated also with pain, and with interfer-
ence with enjoyment of life, activity, relations with others 
and work, while it was positively correlated with interference 
with mood. The absolute values of the correlation coeffi-
cients were mostly ≥0.2, yet invariably <0.4 (Table 2).
In both cohorts, multivariate logistic regression indi-
cated that the rest- activity I < O parameter was significantly 
and independently associated with global quality of life 
(EORTC questionnaire) and interference with enjoyment of 
life (MDASI questionnaire), alongside all the other selected 
PROMs (P < 0.0001 in both instances). Subgroup analyses 
according to sex, PS (0 vs 1 vs 2), and age (median- split) 
in cohort #1 consistently produced relationships between 
I < O on the one hand, and fatigue, anorexia, global qual-
ity of life, physical and social functioning on the other hand 
(Figure 3A).
In cohort #2, day- to- day I < O changes spanned be-
tween −17.0% and +9.1% (median: 0) and the intermedi-
ate tercile included instances with changes within ±0.3%. 
The dynamics for a day to the next confirmed an increased 
F I G U R E  1  Median (and interquartile range) I < O values in the subgroups defined by the terciles of the PROMs items from the EORTC 
(panels A and B) and MDASI (panels C and D) questionnaires: blue, first; gray, second; red, third. In all cases, the higher the tercile, the more 
severe the symptom, except for the EORTC QLQ- C30 domains (panel B), in which the higher the tercile, the better the quality of life and the 
functioning. In all cases, stars indicate P < 0.0001. Other nonsignificant P values are detailed in the Section 3
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severity of fatigue, anorexia, interference with activity, 
relations, and enjoyment when I < O worsened during 
this same time frame (Figure 3B). Altogether, decreased 
symptom severity was also observed whenever I < O 
improved, except for interference with relations with oth-
ers (Figure 3B). Although statistical significance was not 
always reached, the trend of the associations in changes 
appeared consistent.
T A B L E  1  Differences in means and associated effect sizes (Cohen’s d values) between subgroups with circadian disruption (I < O ≤ 97.5%) 
and those with robust circadian function (I < O > 97.5%) for all tested subjective items in each study population
EORTC items [0- 100] (cohort #1) MDASI items [0- 10] (cohort #2)
Difference Cohen’s d P Difference Cohen’s d P
Fatigue 15.5 0.63 <0.001 Fatigue 1.19 0.54 <0.001
Anorexia 18.0 0.58 <0.001 Anorexia 0.79 0.33 <0.001
Sleep trouble 10.3 0.34 0.009 Sleep disturbance 0.14 0.07 0.61
Pain 14.0 0.56 <0.001 Pain 0.53 0.20 0.02
Global Quality of 
Life
−13.0 0.64 <0.001 Interference with Enjoyment 
of Life
1.08 0.48 <0.001
Physical 
Functioning
−15.0 0.61 <0.001 Interference with Activity 1.58 0.73 <0.001
Social 
Functioning
−15.5 0.54 <0.001 Interference with Relations 
with Others
0.57 0.26 <0.001
Role Functioning −10.1 0.31 0.04 Interference with Work 1.57 0.68 <0.001
Positive differences represent higher values when I < O ≤ 97.5%.
F I G U R E  2  Mean (±SEM) values PROMs indices according to high (blue) or low (orange) I < O, indicating robust and disrupted circadian 
rest- activity rhythm, respectively. For symptoms (panel A), in both scales, higher values imply worse symptom severity (range for EORTC: 0- 100; 
for MDASI: 0- 10). In panel B, for the EORTC scale, higher values designate better quality of life domains (range: 0- 100), while for MDASI, lower 
values imply less intense interference (range: 0- 10). For all comparisons, P < 0.001
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4 |  DISCUSSION
The results from two subjective PROMs questionnaires 
(EORTC QLQ- C30 and MDASI) were compared to cir-
cadian rhythm quantitative estimates computed from 
wrist actigraphy records in two cohorts of cancer patients. 
Statistically significant and clinically meaningful associa-
tions were found between circadian rest- activity rhythm al-
terations, and the severity of fatigue and anorexia, as well 
as the impairment of physical and social dimensions of HR- 
QoL and that of general well- being. Indeed, the size of the 
Cohort #1 r P Cohort #2 r P
EORTC items MDASI items
Fatigue −0.33 <0.001 Fatigue −0.26 <0.001
Anorexia −0.29 <0.001 Anorexia −0.17 <0.001
Sleep trouble −0.20 0.002 Sleep disturbance −0.03 0.28
Pain −0.31 <0.001 Pain −0.10 0.001
Global 
quality of 
life
0.33 <0.001 Interference with enjoy-
ment of life
−0.19 <0.001
Physical 
functioning
0.36 <0.001 Interference with activity −0.32 <0.001
Social 
functioning
0.28 <0.001 Interference with relations 
with others
−0.12 <0.001
Role 
functioning
0.19 0.004 Interference with work −0.32 <0.001
T A B L E  2  Spearman’s rank 
correlations between I < O and selected 
items from EORTC QLQ- C30 and MDASI 
questionnaires
F I G U R E  3  Sensitivity subgroup and dynamic analyses. Panel A (cohort #1): difference in mean EORTC item values between patients with 
circadian disruption (I < O ≤ 97.5%) and circadian robustness, in the subgroups defined by sex, PS, and age. For the symptoms, positive values 
reflect worse severity in patients with circadian disruption. For the domains, negative values indicate poorer quality of life in patients with circadian 
disruption. Panel B (cohort #2): mean (±SEM) day- to- day changes in MDASI scores in the subgroups of cases defined by improved (yellow), stable 
(gray), or worsened (blue) circadian function (increased, unchanged, or decreased I < O, respectively). Changes to more severe symptoms the next 
day are associated with negative values
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differences was substantial and medically meaningful.40,41 
Moreover, the relationships between circadian rhythms and 
fatigue or anorexia were strikingly similar in both popula-
tions, in which symptoms and HR- QoL were assessed using 
distinct questionnaires. This observation, particularly when 
taking into account the time difference between the two data 
group collection, as well as complementary subgroup and in-
trasubject dynamic analyses, further supported the reliability 
of the findings. However, circadian rhythm alterations were 
only weakly associated with subjective sleep complaints, in 
line with prior reports.43,44 This underscores the importance 
of obtaining objective as well as subjective reports of sleep 
quality and quantity.45,46
One of our study’s limitations is that it does not provide 
definitive evidence as to whether circadian rhythm disruption 
is a cause, a consequence, or a correlate of fatigue and an-
orexia.47 However, fatigue, anorexia, sleep disturbance, and 
mood alteration, a symptom cluster here linked to altered cir-
cadian rhythm, also characterize both jet lag after long- haul 
transmeridian flights and shift work, two conditions causing 
circadian disruption.8-11 This observation therefore supports 
a causality link between circadian disruption and systemic 
symptoms, as well as reciprocal interactions.
Circadian rhythms rhythmically regulate physical fit-
ness, appetite, mood, and sleep, while in turn, physical 
exercise, timing of meals and eating, sleep quality, and 
duration can reinforce circadian rhythms. Thus, poor cir-
cadian entrainment can also be expected in patients suffer-
ing from severe fatigue, anorexia, physical deterioration, 
or social impairment.48,49 In contrast, those patients with 
mild or no fatigue or physical impairment, good appetite 
and regular social life, likely perform some outdoor ac-
tivity, eat meals at consistent times, and routinely interact 
with others, thus better synchronizing their CTS (Figure 
S3). This hypothesis, supported by the current findings 
and previous reports,42,50,51 has two clinically relevant 
implications. First, interventions developed to resynchro-
nize subjects experiencing jet lag or shift work ought to 
be tested in symptomatic cancer patients with circadian 
disruption, aiming to improve their symptoms through a 
more robust circadian entrainment.52,53 Recent data on be-
havioral treatments for cancer- related fatigue or insomnia 
endorse such novel therapeutic approaches.54,55 However, 
potentially modifiable determinants of circadian disrup-
tion need to be identified on an individual basis, as syn-
chronization interventions will require a personalized 
approach. Second, with the recent rapid development of 
wearable biosensors, it is possible to implement a contin-
uous remote real- time monitoring of relevant behavioral 
and physiological rhythms. Together with the use of elec-
tronic PROMs, this could provide more effective care with 
timely personalized interventions for cancer patients in 
their home environment.30,56-58
In conclusion, we found a consistent and robust as-
sociation between objectively assessed circadian rest- 
activity rhythm and fatigue, anorexia, physical and social 
functioning, as well as global quality of life, primarily 
in patients with advanced or metastatic gastro- intestinal 
cancer. The patients were from different institutions, and 
PROMs were assessed using two distinct internationally 
validated questionnaires.32,33 The study confirmed and 
extended the clinical relevance of the dichotomy index 
I < O, a circadian parameter that is computed from wrist 
actigraphy monitoring time series. Here, we showed 
that I < O was an objective and continuously assessable 
biomarker of selected PROMs, which contributed with 
additional information to HR- QoL, as well as being an in-
dependent prognostic factor of overall survival in cancer 
patients.29,31,35-37 The results support the development and 
testing of interventions targeting the circadian clock to 
relieve drug- refractory systemic symptoms and improve 
HR- QoL in cancer patients.
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